Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis

References

• Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Rheumatoid Arthritis In: Pelechas E, editor. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Cham: Springer; 2019:45–76.
   Google Scholar
• Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–130. doi:10.1016/j.semarthrit.2014.05.00124973898
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi:10.1016/S0140-6736(16)30173-827156434
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–188. doi:10.1016/j.semarthrit.2006.08.00617045630
   PubMed Web of Science ®Google Scholar
• Brooks PM. The burden of musculoskeletal disease – a global perspective. Clin Rheumatol. 2006;25(6):778–781. doi:10.1007/s10067-006-0240-316609823
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al.; for the American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68;2016:1–25. doi:10.1002/acr.2278326545825
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317–322. doi:10.1080/14712598.2018.143076029350566
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173–179. doi:10.1080/14712598.2019.156645630616405
   PubMed Web of Science ®Google Scholar
• Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014;66:1604–1611. doi:10.1002/acr.2238324942466
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. 2019;48(4):597–602. doi:10.1016/j.semarthrit.2018.06.00330075990
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Rheumatoid arthritis treatment. A back to the drawing board project or high expectations for low unmet needs? J Clin Med. 2019;8(8):pii.E1237. doi:10.3390/jcm8081237
   Web of Science ®Google Scholar
• Regeneron. Regeneron and Sanofi announce FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients; Press release 5 22, 2017 Available from: http://investor.regeneron.com/releaseDetail.cfm?releaseid=1027419. Accessed 526, 2019.
   Google Scholar
• Hennigan S, Kavanaugh A. Interleukin-6 in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008;4(4):767–775. doi:10.2147/tcrm.s347019209259
   PubMedGoogle Scholar
• Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl 5):v3–v11. doi:10.1093/rheumatology/kes11322718924
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. doi:10.1155/2014/69831324524085
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015;67(10):2591–2600. doi:10.1002/art.3924926138593
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of Olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. doi:10.1136/annrheumdis-2013-20476024641941
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(6):755–763. doi:10.1080/14712598.2017.131509928374627
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf. Accessed 527, 2019.
   Google Scholar
• Regeneron Pharmaceuticals INC/Sanofi-Aventis US LLC. Kevzara (package insert). New York, NY: Regeneron Pharmaceuticals INC/Sanofi Aventis US LLC. Available from: http://products.sanofi.us/kevzara/kevzara.pdf. Accessed 530, 2019.
   Google Scholar
• U.S. National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov/ct2/results?term=sarilumab&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=g&recrs=h&recrs=e&recrs=i&recrs=m&age_v=&gndr=&type=&rslt=. Accessed 62, 2019.
   Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–1634. doi:10.1136/annrheumdis-2013-20440524297381
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–1437. doi:10.1002/art.3909325733246
   PubMed Web of Science ®Google Scholar
• Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or inteolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277–290. doi:10.1002/art.3994427860410
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840–847. doi:10.1136/annrheumdis-2016-21031027856432
   PubMed Web of Science ®Google Scholar
• Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5(1):231–242. doi:10.1007/s40744-017-0090-229209946
   PubMed Web of Science ®Google Scholar
• Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018. doi:10.1093/rheumatology/key361
   Google Scholar
• Wells AF, Parrino J, Mangan EK, et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol Ther. 2019;6:339–352. doi:10.1007/s40744-019-0157-331090044
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01764997?term=NCT01764997&rank=1&view=results. Accessed 822, 2019.
   Google Scholar
• U.S. National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov/ct2/show/NCT01217814?term=NCT01217814&rank=1. Accessed 822, 2019.
   Google Scholar
• U.S. National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov/ct2/show/NCT02293902. Accessed 822, 2019
   Google Scholar
• Tanaka Y, Wada K, Takahashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi:10.1186/s13075-019-1856-430894208
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Clinical Trials. Available from: https://clinicaltrials.gov/ct2/results?term=sarilumab&Search=Apply&recrs=b&recrs=a&recrs=g&recrs=h&recrs=i&age_v=&gndr=&type=&rslt=. Accessed 62, 2019.
   Google Scholar